This association between BAFF and active liver inflammation is also evident during AIH relapse, highlighting its potential role in disease progression [21,22]. A multicenter phase II/III trial (NCT03217422) is underway to estimate the efficacy of ianalumab (another BAFF receptor inhibitor) in patients with AIH non-responding to standard treatment. This evidence concerns the gene TNFSF13B and autoimmune hepatitis.